Volume 74, Issue 6, Pages (September 2008)

Slides:



Advertisements
Similar presentations
Hypothesis: an erythropoietin honeymoon phase exists
Advertisements

Volume 65, Issue 6, Pages (June 2004)
Volume 81, Issue 5, Pages (March 2012)
Volume 153, Issue 3, Pages e7 (September 2017)
Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations.
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
Volume 153, Issue 3, Pages e7 (September 2017)
Volume 83, Issue 3, Pages (March 2013)
Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 
Evaluation of tumor necrosis factor-α, interleukin-6 and C-reactive protein plasma levels as predictors of bacteremia in patients presenting signs of.
Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure  Steven Fishbane, Nobuyuki Miyawaki  Kidney International 
Volume 80, Issue 11, Pages (December 2011)
Volume 88, Issue 5, Pages (November 2015)
C-reactive protein and dialysis access
ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target  Szu-Chun Hung, Der-Cherng Tarng  Kidney International 
Prehypertension and chronic kidney disease: the ox or the plow?
Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007  Joanna M. Smith, Susan A. Mott,
Reassessment of the care of the patient with chronic kidney disease
Corrections to "Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated.
C-reactive protein and dialysis access
John P. Middleton, Patrick H. Pun  Kidney International 
Volume 79, Issue 5, Pages (March 2011)
Volume 54, Issue 2, Pages (August 1998)
Yasuhiro Hamada, Masafumi Fukagawa  Kidney International 
Volume 85, Issue 3, Pages (March 2014)
Jeffrey C. Fink, Glenn M. Chertow  Kidney International 
Volume 70, Pages S21-S25 (December 2006)
Chapter 4: Red cell transfusion to treat anemia in CKD
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Volume 73, Issue 5, Pages (March 2008)
Comorbidity and confounding in end-stage renal disease
The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis  Sai Subhodhini Reddy, Jean L. Holley 
Volume 74, Issue 3, Pages (August 2008)
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Reducing lipids for CV protection in CKD patients—current evidence
Use of vitamin D in chronic kidney disease patients
Acute coronary syndrome in ESRD patients
Volume 86, Issue 1, Pages (July 2014)
Volume 81, Issue 5, Pages (March 2012)
Volume 71, Issue 3, Pages (February 2007)
Volume 65, Issue 6, Pages (June 2004)
Volume 73, Issue 12, Pages (June 2008)
The dynamics of prognostic indicators: toward earlier identification of dialysis patients with a high risk of dying  Charles Chazot, Guillaume Jean  Kidney.
Volume 76, Issue 6, Pages (September 2009)
Günter Weiss, Florian Kronenberg  Kidney International 
Francesco Locatelli, Lucia Del Vecchio  Kidney International 
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Volume 74, Issue 8, Pages (October 2008)
Methods for guideline development
Volume 67, Issue 4, Pages (April 2005)
Volume 78, Issue 5, Pages (September 2010)
Nephrology Crossword: Glomerulonephritis
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Volume 62, Issue 4, Pages (October 2002)
Volume 80, Issue 11, Pages (December 2011)
Cardio-Kidney-Damage: a unifying concept
K. Kalantar-Zadeh, J. D. Kopple, N. Kamranpour, A. M. Fogelman, M
Volume 80, Issue 10, Pages (November 2011)
The hypothesis that abnormal BH4 metabolism impairs kidney function
Toward a B-cell signature of tolerance?
Sundararaman Swaminathan, Matthew D. Griffin  Kidney International 
Volume 75, Issue 7, Pages (April 2009)
Vitamin D deficiency and anemia in early chronic kidney disease
Adiponectin: good, bad, or just plain ugly?
Hisataka Kobayashi, Peter L. Choyke  Kidney International 
In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression  B.O. Eriksen, O.C. Ingebretsen  Kidney.
Volume 74, Issue 10, Pages (November 2008)
The prevalence of hematologic and metabolic abnormalities during chronic kidney disease stages in different ethnic groups  S.J. Barbour, L. Er, O. Djurdjev,
Volume 74, Pages S4-S9 (December 2008)
Presentation transcript:

Volume 74, Issue 6, Pages 782-790 (September 2008) Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease  Sai Ram Keithi-Reddy, Francesco Addabbo, Tejas V. Patel, Bharati V. Mittal, Michael S. Goligorsky, Ajay K. Singh  Kidney International  Volume 74, Issue 6, Pages 782-790 (September 2008) DOI: 10.1038/ki.2008.245 Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 1 Number of anemic patients and patients on ESAs by tertiles of CRP in CKD cohort. Among anemic subjects, 35.9% were in the third tertile whereas 33% were in the first tertile for CRP (Mantel–Haenszel test for linear association; P=0.58) (a). Fifty percentage of the anemic subjects on ESAs were in the third tertile whereas 33% of epo-naive patients were in the third tertile for CRP (Mantel–Haenszel test for linear association; P=0.013). Patients in the first and third tertiles were compared for P-value (b). CKD, chronic kidney disease; CRP, C-reactive protein; ESAs, erythropoiesis-stimulating agents. Kidney International 2008 74, 782-790DOI: (10.1038/ki.2008.245) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 2 Odds ratios for upper two quartiles for patients treated with ESAs. In all, 71.4% of the patients on ESAs were in upper two quartiles for IL-6 compared to 51.9% of ESA-naive anemic and 40.4% of non-anemic patients with unadjusted odds of 3.6 (a). In all, 76.2% of the patients on ESAs were in upper two quartiles for IL-8 compared to 59.3% of ESA-naive anemic and 34.6% of non-anemic patients with unadjusted odds of 6.0 (b). In total, 71.4% of the patients on ESAs were in upper two quartiles for TNF-α compared to 55.6% of ESA-naive anemic and 38.5% of non-anemic patients with unadjusted odds of 4.0 (c). Sixty percentage of the patients on ESAs were in the upper two quartiles for Ferritin compared to 44% of ESA-naive anemic and 48.9% of non-anemic patients with unadjusted odds of 1.5 (d). A total of 61.9% of the patients on ESAs were in the lower two quartiles for albumin compared to 77.8% of ESA-naive anemic and 34.6% of non-anemic patients with unadjusted odds of 6.0 (e). Odds ratios are for the use of ESAs. *Lower two and upper two quartiles are represented in reverse order for the convenience of readers. ESAs, erythropoiesis-stimulating agents; IL, interleukin; TNF-α, tumor necrosis factor-α. Kidney International 2008 74, 782-790DOI: (10.1038/ki.2008.245) Copyright © 2008 International Society of Nephrology Terms and Conditions